NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the need for broad resistance coverage, avoidance of clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Horan, Joshua C., Tangpeerachaikul, Anupong, Besse, Benjamin, Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Camidge, D. Ross, van der Wekken, Anthonie J., Nguyen-Phuong, Linh, Acker, Adam, Keddy, Clare, Nicholson, Katelyn S., Yoda, Satoshi, Mente, Scot, Sun, Yuting, Soglia, John R., Kohl, Nancy E., Porter, James R., Shair, Matthew D., Zhu, Viola, Davare, Monika A., Hata, Aaron N., Pelish, Henry E., Lin, Jessica J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975673/
https://www.ncbi.nlm.nih.gov/pubmed/36511802
http://dx.doi.org/10.1158/2159-8290.CD-22-0968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975673/
https://www.ncbi.nlm.nih.gov/pubmed/36511802
http://dx.doi.org/10.1158/2159-8290.CD-22-0968

Ejemplares similares